ONLINE

SPARK-BIH Lecture

Critical Facts about Writing an Investigational Medicinal Product Dossier (IMPD) for Successful Clinical Trial Applications

22 March 2022 | 4 – 5 pm (CET) | Dr. Carola Krause & Abraham F. Shevack

What is the IMPD and why is it so relevant early in the drug development process? What to consider? What do professional medical writers do and how do you get support from them?

The **Investigational Medicinal Product Dossier (IMPD)** is a central piece of documents required for approval of clinical trial applications by the regulatory authorities in the EU. The IMPD contributes to the overall success of drug development programs, and, for a first-in-human clinical trial, it is the initial document to assemble all obtained research data.

In this Online Educational Forum Lecture "Critical Facts about Writing an Investigational Medicinal Product Dossier (IMPD) for Successful Clinical Trial Applications", **Dr. Carola Krause, President of the European Medical Writers Association (EMWA)**, and **Abraham F. Shevack, past-President of the EMWA**, will tell us about what to consider when preparing an IMPD for clinical trial applications and how you get support from professional medical writers.

Online via GoToMeeting | Please register here!

Registration to the webinar is required in advance. Please register no later than March 21, 2022. Please note that you will receive the Microsoft Teams link the evening before the lecture and that access to last minute registrations, cannot be guaranteed.

spark-bih.de
bihealth.org

SPARK is an initiative created at Stanford University, to overcome challenges associated with translation of academic discoveries.